Back to top
more

Envista (NVST)

(Delayed Data from NYSE)

$21.10 USD

21.10
1,979,088

-0.03 (-0.14%)

Updated Sep 16, 2025 03:59 PM ET

After-Market: $21.50 +0.40 (1.90%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is it Worth Retaining ResMed Stock in Your Portfolio Now?

by Zacks Equity Research

RMD's Mask and Device sales fuel growth, but macro headwinds and fierce competition continue to challenge its performance.

Zacks Equity Research

Zacks.com featured highlights include Post Holdings, Pediatrix Medical, Envista and Zions Bancorporation

by Zacks Equity Research

Post Holdings, Pediatrix, Envista, and Zions Bancorporation hit 52-week highs as growth, cash flow, and upgrades fuel momentum.

Zacks Equity Research

New Strong Buy Stocks for September 2nd

by Zacks Equity Research

RSI, UDMY, NVST, DORM and CFBK have been added to the Zacks Rank #1 (Strong Buy) List on September 2, 2025.

Zacks Equity Research

Charles River Stock May Benefit From Joining EASYGEN Consortium

by Zacks Equity Research

CRL joins EASYGEN to speed CAR-T therapy delivery, which may boost patient access and investor sentiment.

Zacks Equity Research

Is it Apt to Hold Bio-Rad Stock in Your Portfolio Now?

by Zacks Equity Research

BIO's strong ddPCR growth and solid diagnostics demand support its stock despite market pressures and stiff competition.

Zacks Equity Research

ABT Stock Gains From Navitor's Expanded Indication Approval in Europe

by Zacks Equity Research

Abbott wins CE Mark in Europe for expanded Navitor use, boosting its Structural Heart business and lifting ABT stock.

Zacks Equity Research

Envista (NVST) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Envista (NVST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Vasundhara Sawalka headshot

4 Stocks Trading Near 52-Week High With Room to Rise Further

by Vasundhara Sawalka

Investors target stocks that have been on a bullish run. Stocks like POST, MD, NVST and ZION are seeing price strength, and the momentum is likely to continue.

Zacks Equity Research

DGX Stock Gains Following a New Joint Venture With Corewell Health

by Zacks Equity Research

Quest Diagnostics shares rise after forming a joint venture with Corewell Health to expand advanced lab services across Michigan.

Zacks Equity Research

Should You Continue to Hold Thermo Fisher Stock in Your Portfolio?

by Zacks Equity Research

TMO's growth, driven by new partnerships and strong end markets, faces challenges from macro pressures and fierce competition.

Zacks Equity Research

Should You Add Zimmer Biomet Stock to Your Portfolio Now?

by Zacks Equity Research

ZBH rides on knee innovation and robotics growth, but debt and macro pressures challenge its upside potential.

Zacks Equity Research

Should You Add IDEXX Stock to Your Portfolio Right Now?

by Zacks Equity Research

IDXX gains from strong CAG Diagnostics growth and rising cloud software demand, but debt levels remain a concern for investors.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Is it the Right Time to Hold Labcorp Stock in Your Portfolio?

by Zacks Equity Research

LH witnesses growth in specialty testing and strategic acquisitions, but macro and currency headwinds remain a concern.

Zacks Equity Research

NVST or ABT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NVST vs. ABT: Which Stock Is the Better Value Option?

Zacks Equity Research

NVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve

by Zacks Equity Research

enVVeno Medical shares plunge after the FDA rejects its VenoValve PMA, citing insufficient trial data and safety concerns tied to the surgical procedure.

Zacks Equity Research

IDEXX Gains 56.2% in a Year: What's Driving the Rally?

by Zacks Equity Research

IDXX shares surge 56.2% in a year, fueled by strong diagnostics growth, cloud software gains and an upbeat 2025 outlook.

Zacks Equity Research

NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer

by Zacks Equity Research

NovoCure submits a PMA to the FDA for TTFields therapy in pancreatic cancer, aiming to expand its oncology reach.

Zacks Equity Research

Insulet Gains 77.2% in a Year: What's Driving the Rally?

by Zacks Equity Research

PODD's 77.2% stock surge is fueled by Omnipod 5 expansion, global launches, strong Q2 profits and robust financial stability.

Zacks Equity Research

Should Boston Scientific Stock Be in Your Portfolio Right Now?

by Zacks Equity Research

BSX's global expansion and MedSurg growth boost Q2 momentum, though currency and macro headwinds weigh on the same.

Zacks Equity Research

Should Quest Diagnostics Stock Be in Your Portfolio Right Now?

by Zacks Equity Research

DGX drives growth with advanced diagnostics, acquisitions and cost savings, but rising debt and macro risks weigh on its outlook.

Zacks Equity Research

Teleflex Stock Gains Following Barrigel's Launch in Japan

by Zacks Equity Research

TFX stock jumps 3.7% after launching Barrigel in Japan, marking a milestone in its global expansion strategy.

Zacks Equity Research

PAHC Stock Up 76.4% in a Year: What's Driving the Rally?

by Zacks Equity Research

Phibro Animal Health's 76.4% stock surge is fueled by strong sales recovery, global growth and a robust balance sheet.

Zacks Equity Research

Labcorp Debuts First FDA-Cleared Blood Test for Alzheimer's, Stock Up

by Zacks Equity Research

LH launches the first FDA-cleared blood test for Alzheimer's, boosting access to early diagnosis and nudging its stock higher.

Zacks Equity Research

Zacks Industry Outlook Highlights Envista, BioLife Solutions, InfuSystems and MariMed

by Zacks Equity Research

Despite industry headwinds, Envista, BioLife Solutions, InfuSystems and MariMed are leveraging innovation and strategy for growth.